Item 15. Exhibits and Financial Statement Schedules.
53K characters. Original on sec.gov · Markdown
Item 15. Exhibits and Financial Statement Schedules.
(a) Index to Consolidated Financial Statements and Schedules
| Page | |||||
| Consolidated Statements of Earnings for the years ended December 31, 2024, 2023 and 2022 | 76 | ||||
| Consolidated Statements of Comprehensive Earnings for the years ended December 31, 2024, 2023 and 2022 | 77 | ||||
| Consolidated Balance Sheets at December 31, 2024 and 2023 | 78 - 79 | ||||
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022 | 80 - 81 | ||||
| Consolidated Statements of Stockholders’ (Deficit) Equity for the years ended December 31, 2024, 2023 and 2022 | 82 | ||||
| Notes to Consolidated Financial Statements | 83 - 142 | ||||
| Report of Independent Registered Public Accounting Firm (PCAOB ID 1358) | 143 - 145 | ||||
| Report of Management on Internal Control Over Financial Reporting | 146 |
Schedules have been omitted either because such schedules are not required or are not applicable.
(b) The following exhibits are filed as part of this Report:
| 101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase. | ||||||||||||
| 101.DEF | — | XBRL Taxonomy Extension Definition Linkbase. | ||||||||||||
| 101.LAB | — | XBRL Taxonomy Extension Label Linkbase. | ||||||||||||
| 101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase. | ||||||||||||
| 104 | — | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
- Denotes management contract or compensatory plan or arrangement in which directors or executive officers are eligible to participate.
** Schedules and certain portions of this exhibit have been omitted pursuant to Item 601(a)(5) and Item 601(b)(10)(iv) of Regulation S-K.
x Denotes exhibits filed herewith.
The exhibits filed herewith do not include certain instruments with respect to long-term debt of PMI, inasmuch as the total amount of debt authorized under any such instrument does not exceed 10 percent of the total assets of PMI on a consolidated basis. PMI agrees, pursuant to Item 601(b)(4)(iii) of Regulation S-K, that it will furnish a copy of any such instrument to the SEC upon request.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PHILIP MORRIS INTERNATIONAL INC. | |||||
| By: | /s/ JACEK OLCZAK | ||||
| (Jacek Olczak Chief Executive Officer) |
Date: February 6, 2025
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacek Olczak, Emmanuel Babeau, and Darlene Quashie Henry and each of them, acting individually, as his or her true and lawful attorney-in-fact, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K for the year ended December 31, 2024, and other documents in connection herewith and therewith, and to file the same, with all exhibits thereto, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection herewith and therewith and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated:
| Signature | Title | Date | ||||||
| /s/ JACEK OLCZAK | Chief Executive Officer and Director | February 6, 2025 | ||||||
| (Jacek Olczak) | ||||||||
| /s/ EMMANUEL BABEAU | Chief Financial Officer | February 6, 2025 | ||||||
| (Emmanuel Babeau) | ||||||||
| /s/ REGINALDO DOBROWOLSKI | Vice President and Controller | February 6, 2025 | ||||||
| (Reginaldo Dobrowolski) | ||||||||
| /s/ ANDRÉ CALANTZOPOULOS | Non-Executive Chairman | February 6, 2025 | ||||||
| (André Calantzopoulos) | ||||||||
| /s/ BONIN BOUGH | Director | February 6, 2025 | ||||||
| (Bonin Bough) | ||||||||
| /s/ MICHEL COMBES | Director | February 6, 2025 | ||||||
| (Michel Combes) | ||||||||
| /s/ DR. JUAN JOSÉ DABOUB | Director | February 6, 2025 | ||||||
| (Juan José Daboub) |
| /s/ WERNER GEISSLER | Director | February 6, 2025 | ||||||
| (Werner Geissler) | ||||||||
| /s/ VICTORIA HARKER | Director | February 6, 2025 | ||||||
| (Victoria Harker) | ||||||||
| /s/ LISA A. HOOK | Director | February 6, 2025 | ||||||
| (Lisa A. Hook) | ||||||||
| /s/ KALPANA MORPARIA | Director | February 6, 2025 | ||||||
| (Kalpana Morparia) | ||||||||
| /s/ ROBERT B. POLET | Director | February 6, 2025 | ||||||
| (Robert B. Polet) | ||||||||
| /s/ DESSISLAVA TEMPERLEY | Director | February 6, 2025 | ||||||
| (Dessislava Temperley) | ||||||||
| /s/ SHLOMO YANAI | Director | February 6, 2025 | ||||||
| (Shlomo Yanai) |
Previous: Item 14. Principal Accounting Fees and Services.